Serum NfL , GFAP , and p‐tau217 in adults with drug‐resistant epilepsy and intellectual disabilities: Signs of ongoing neural injury | Synapse
April 1, 2026Open Access
Serum NfL , GFAP , and p‐tau217 in adults with drug‐resistant epilepsy and intellectual disabilities: Signs of ongoing neural injury
Key Points
To investigate the levels of serum NfL, GFAP, and p-tau217 in adults with drug-resistant epilepsy and intellectual disabilities, focusing on indicating neural injury.
Measured serum levels of NfL, GFAP, and p-tau217 in participants.
Compared clinical outcomes with serum biomarker levels.
Analyzed findings to assess the relationship between biomarkers and clinical decline.
High levels of NfL and GFAP were detected in many participants.
Increased biomarker levels coincided with observed clinical decline.
Findings suggest ongoing neural injury, though not directly linked to Alzheimer's disease (AD).
Abstract
NfL and GFAP were abnormal in many participants, coinciding with clinical decline. Findings are suggestive for ongoing neural injury, but not necessarily for AD.